Treating latent tuberculosis with rifampin: Is it the cheaper option?

Thorax

Volumn 65, Issue 7, 2010, Pages 572-573

  Stout, Jason E ^a   Holland, David P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FUNDING; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; TUBERCULOSIS CONTROL; UNITED STATES; VOMITING; ECONOMICS; NOTE; STATISTICS;

ANTIBIOTICS, ANTITUBERCULAR; HEALTH CARE COSTS; HUMANS; LATENT TUBERCULOSIS; RIFAMPIN;

EID: 77955291494     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.138685     Document Type: Editorial

References (9)

1. Sterling TR, Bethel J, Goldberg S, et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006;173:927-31.
2. Horsburgh CR Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-9.
3. Aspler A, Long R, Trajman A, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010;65:582-7.
4. Anon. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1-51.
5. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009;49:1883-9.
6. Holland DP, Sanders GD, Hamilton CD, et al. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055-60.
7. Young H, Wessolossky M, Ellis J, et al. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts. Clin Infect Dis 2009;49:424-7.
8. Livengood JR, Sigler TG, Foster LR, et al. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. JAMA 1985;253:2847-9.
9. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009;14:1039-43.